Abstract

The aim of the study was to study the effectiveness of the use of protected cephalosporin III generation Extum in the treatment of community-acquired pneumonia in children. The study included 100 children with community-acquired pneumonia at the age from 1 to 15 years, who were observed and treated in the department of pulmonology. In the process of complex clinical and laboratory examination of children, biochemical, microbiological and immunological research methods were used. Microbiological studies have shown that in children with community-acquired pneumonia, S. Pneumonia occupies a significant place in the etiological structure and accounts for 42.0% of cases, a high sensitivity of pneumococcus to injectable cephalosporin of the third generation has been established. When included in complex treatment, protected cephalosporin of the third generation Extum leads to a decrease in the frequency of repeated acute respiratory infections and their complications by 2.2 times, the frequency of recurrent bronchitis and pneumonia by 1.7 times, which indicates a high therapeutic effectiveness of the proposed treatment